Aviragen Therapeutics Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of Teslexivir (BTA074) for the Treatment of Condyloma
Atea Pharmaceuticals, Inc. - common stock (AVIR)
US:NASDAQ Investor Relations:
investors.aviragentherapeutics.com/news-releases/news-release-details/aviragen-therapeutics-and-vaxart-enter-merger-agreement
Company Research
Source: GlobeNewswire
ATLANTA, Nov. 29, 2017 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR), a company focused on the discovery and development of direct-acting antivirals to treat infections that have limited therapeutic options, today announced the completion of patient enrollment in its Phase 2 CT4 clinical trial evaluating teslexivir (BTA074) for the treatment of condyloma. The Company expects to report top-line data from this trial in the second quarter of 2018. “The enrollment and randomization of over 210 patients in the CT4 trial represents a significant milestone in the development of teslexivir,” said Joseph Patti, Ph.D., President and Chief Executive Officer of Aviragen. “We believe the direct-acting antiviral mechanism of action of teslexivir has the potential to both enhance clearance rates and reduce condyloma recurrence rates compared with currently approved treatments.” CT4 is a Phase 2 double-blind, randomized, multi-center, placebo-controlled trial designed to evaluate
Show less
Read more
Impact Snapshot
Event Time:
AVIR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AVIR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AVIR alerts
High impacting Atea Pharmaceuticals, Inc. - common stock news events
Weekly update
A roundup of the hottest topics
AVIR
News
- Is Atea Pharmaceuticals (AVIR) Stock Outpacing Its Medical Peers This Year? [Yahoo! Finance]Yahoo! Finance
- Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD's The Liver Meeting 2024 [Yahoo! Finance]Yahoo! Finance
- Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024GlobeNewswire
- Atea Pharmaceuticals Inc (AVIR) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst ... [Yahoo! Finance]Yahoo! Finance
- Atea Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswire
AVIR
Earnings
- 11/7/24 - Beat
AVIR
Sec Filings
- 11/20/24 - Form EFFECT
- 11/15/24 - Form SC
- 11/12/24 - Form SC
- AVIR's page on the SEC website